FDA's reviews of new drugs : changes needed in process for reviewing and reporting on clinical studies /

Medical device reporting : improvements needed in FDA's system for monitoring problems with approved devices : report to Congressional committees /

United States. General Accounting Office.

"B-266228"--P. 1."GAO/HEHS-97-21.""January 1997."Cover title.Includes bibliographical references (p....

The Food and Drug Administration's process for approving new drugs : report /

United States. Congress. House. Committee on Science and Technology. Subcommittee on Science, Research, and Technology.

"November 1980.""Serial HHH."At head of title: Committee print.Includes bibliographical references.M...

Revitalizing new product development from clinical trials through FDA review : hearing of the Committee on Labor and Human Resources, United States Senate, One Hundred Fourth Congress, second session, on S. 1477 ... February 21, 1996.

United States. Congress. Senate. Committee on Labor and Human Resources.

January 1996

Shipping list no.: 96-0240-P.Distributed to some depository libraries in microfiche.Includes bibliog...

Prescription drugs : information on selected drug utilization review systems : report to the Chairman, Special Committee on Aging, U.S. Senate/

United States. General Accounting Office.

January 1989

Running title: Prescription drug utilization review systems."GAO/PEMD-89-18""May 1989."Cover title.M...

FDA drug review : postapproval risks, 1976-85 : report to the Chairman, Subcommittee on Human Resources and Intergovernmental Relations, Committee on Government Operations, House of Representatives.

United States. General Accounting Office.

"B-235944"--P. [1]"GAO/PEMD-90-15.""April 1990."Cover title.Includes bibliographical references (p. ...

Medical devices : FDA review time : report to the Chairman, Subcommittee on Oversight and Investigations, Committee on Commerce, House of Representatives /

United States. General Accounting Office.
United States. Congress. House. Committee on Commerce. Subcommittee on Oversight and Investigations.

"B-261822"--P. 1."GAO/PEMD-96-2.""October 1995."Cover title.Includes bibliographical references.Mode...

FDA drug approval : review time has decreased in recent years : report to Congressional requesters /

United States. General Accounting Office.

"B-266023"--P. 1."GAO/PEMD-96-1.""October 1995."Cover title.Includes bibliographical references.Mode...

Medicare : prescription drug issues : report to the chairman, Special Committee on Aging, U.S. Senate /

United States. General Accounting Office.
United States. Congress. Senate. Special Committee on Aging.

"B-227664"--P. 1."GAO/PEMD-87-20.""July 1987.""Program Evaluation and Methodology Division"--P. 1.Co...

Medicare, an assessment of HCFA's 1988 hospital mortality analyses : briefing report to the ranking minority member, Special Committee on Aging, U.S. Senate /

United States. General Accounting Office.

Running title: GAO/PEMD-89-11BR HCFA hospital mortality analyses."GAO/PEMD-89-11BR""December 1988"Co...

Medicare : issues concerning the HealthChoice demonstration project : report to the ranking minority member, Special Committee on Aging, U.S. Senate /

United States. General Accounting Office.

"B-204545"--P. 1."GAO/HRD-88-69.""July 1988."Cover title.Mode of access: Internet

Medical devices : FDA's 510(k) operations could be improved : report to the chairman, Subcommittee on Health and the Environment, Committee on Energy and Commerce, House of Representative /

United States. General Accounting Office.
United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment.

"B-229400"--p. [1]"GAO/PEMD-88-14""August 1988"Running title: FDA's implementation of premarket noti...

Medicare : better controls needed for peer review organizations' evaluations : report to the Subcommittee on Health, Committee on Finance, U.S. Senate /

United States. General Accounting Office.
United States. Congress. Senate. Committee on Finance. Subcommittee on Health.

"B-229169"--P. [1]"GAO/HRD-88-13.""October 1987."Cover title.Mode of access: Internet

Food safety and quality : FDA needs stronger controls over the approval process for new animal drugs : report to the Chairman, Human Resources and Intergovernmental Relations Subcommittee, Committee on Government Operations, House of Representatives /

United States. General Accounting Office.
United States. Congress. House of Representatives. Committee on Government Operations. Human Resources and Intergovernmental Relaltions Subcommittee.

"B-246269"--P. 1."GAO/RCED-92-63.""January 1992."Cover title.Includes bibliographical references.Mod...

Prescription drugs : HCFA's proposed drug utilization review system ignores quality of care issues : briefing report to the Chairman, Special Committee on Aging, U.S. Senate/

United States. General Accounting Office.
United States. Congress. Senate. Special Committee on Aging.

January 1989

"B-235298"--p.1."GAO/PEMD-89-26BR""July 1989"Cover title.Contains bibliographic references.Mode of a...

FDA review times : statement of Mary R. Hamilton, Director of Program Evaluation in Human Services Areas, Program Evaluation and Methodology Division, before the Subcommittee on Health and Environment, Committee on Commerce, House of Representatives /

Hamilton, Mary R.
United States. Congress. House. Committee on Commerce. Subcommittee on Health and the Environment.
United States. General Accounting Office.

"For release ... 10:00 a.m. EST Thursday May 2, 1996."Cover title.Includes bibliographical reference...

Medical device reporting : improvements needed in FDA's system for monitoring problems with approved devices : report to Congressional committees /

United States. General Accounting Office.

"B-266228"--P. 1."GAO/HEHS-97-21.""January 1997."Cover title.Includes bibliographical references (p....

The Food and Drug Administration's process for approving new drugs : report /

United States. Congress. House. Committee on Science and Technology. Subcommittee on Science, Research, and Technology.

"November 1980.""Serial HHH."At head of title: Committee print.Includes bibliographical references.M...

Revitalizing new product development from clinical trials through FDA review : hearing of the Committee on Labor and Human Resources, United States Senate, One Hundred Fourth Congress, second session, on S. 1477 ... February 21, 1996.

United States. Congress. Senate. Committee on Labor and Human Resources.

January 1996

Shipping list no.: 96-0240-P.Distributed to some depository libraries in microfiche.Includes bibliog...

Prescription drugs : information on selected drug utilization review systems : report to the Chairman, Special Committee on Aging, U.S. Senate/

United States. General Accounting Office.

January 1989

Running title: Prescription drug utilization review systems."GAO/PEMD-89-18""May 1989."Cover title.M...

FDA drug review : postapproval risks, 1976-85 : report to the Chairman, Subcommittee on Human Resources and Intergovernmental Relations, Committee on Government Operations, House of Representatives.

United States. General Accounting Office.

"B-235944"--P. [1]"GAO/PEMD-90-15.""April 1990."Cover title.Includes bibliographical references (p. ...

Medical devices : FDA review time : report to the Chairman, Subcommittee on Oversight and Investigations, Committee on Commerce, House of Representatives /

United States. General Accounting Office.
United States. Congress. House. Committee on Commerce. Subcommittee on Oversight and Investigations.

"B-261822"--P. 1."GAO/PEMD-96-2.""October 1995."Cover title.Includes bibliographical references.Mode...

FDA drug approval : review time has decreased in recent years : report to Congressional requesters /

United States. General Accounting Office.

"B-266023"--P. 1."GAO/PEMD-96-1.""October 1995."Cover title.Includes bibliographical references.Mode...

Medicare : prescription drug issues : report to the chairman, Special Committee on Aging, U.S. Senate /

United States. General Accounting Office.
United States. Congress. Senate. Special Committee on Aging.

"B-227664"--P. 1."GAO/PEMD-87-20.""July 1987.""Program Evaluation and Methodology Division"--P. 1.Co...

Medicare, an assessment of HCFA's 1988 hospital mortality analyses : briefing report to the ranking minority member, Special Committee on Aging, U.S. Senate /

United States. General Accounting Office.

Running title: GAO/PEMD-89-11BR HCFA hospital mortality analyses."GAO/PEMD-89-11BR""December 1988"Co...

Medicare : issues concerning the HealthChoice demonstration project : report to the ranking minority member, Special Committee on Aging, U.S. Senate /

United States. General Accounting Office.

"B-204545"--P. 1."GAO/HRD-88-69.""July 1988."Cover title.Mode of access: Internet

Medical devices : FDA's 510(k) operations could be improved : report to the chairman, Subcommittee on Health and the Environment, Committee on Energy and Commerce, House of Representative /

United States. General Accounting Office.
United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health and the Environment.

"B-229400"--p. [1]"GAO/PEMD-88-14""August 1988"Running title: FDA's implementation of premarket noti...

Medicare : better controls needed for peer review organizations' evaluations : report to the Subcommittee on Health, Committee on Finance, U.S. Senate /

United States. General Accounting Office.
United States. Congress. Senate. Committee on Finance. Subcommittee on Health.

"B-229169"--P. [1]"GAO/HRD-88-13.""October 1987."Cover title.Mode of access: Internet

Food safety and quality : FDA needs stronger controls over the approval process for new animal drugs : report to the Chairman, Human Resources and Intergovernmental Relations Subcommittee, Committee on Government Operations, House of Representatives /

United States. General Accounting Office.
United States. Congress. House of Representatives. Committee on Government Operations. Human Resources and Intergovernmental Relaltions Subcommittee.

"B-246269"--P. 1."GAO/RCED-92-63.""January 1992."Cover title.Includes bibliographical references.Mod...

Prescription drugs : HCFA's proposed drug utilization review system ignores quality of care issues : briefing report to the Chairman, Special Committee on Aging, U.S. Senate/

United States. General Accounting Office.
United States. Congress. Senate. Special Committee on Aging.

January 1989

"B-235298"--p.1."GAO/PEMD-89-26BR""July 1989"Cover title.Contains bibliographic references.Mode of a...

FDA review times : statement of Mary R. Hamilton, Director of Program Evaluation in Human Services Areas, Program Evaluation and Methodology Division, before the Subcommittee on Health and Environment, Committee on Commerce, House of Representatives /

Hamilton, Mary R.
United States. Congress. House. Committee on Commerce. Subcommittee on Health and the Environment.
United States. General Accounting Office.

"For release ... 10:00 a.m. EST Thursday May 2, 1996."Cover title.Includes bibliographical reference...

Medical device reporting : improvements needed in FDA's system for monitoring problems with approved devices : report to Congressional committees /

United States. General Accounting Office.

"B-266228"--P. 1."GAO/HEHS-97-21.""January 1997."Cover title.Includes bibliographical references (p....

The Food and Drug Administration's process for approving new drugs : report /

United States. Congress. House. Committee on Science and Technology. Subcommittee on Science, Research, and Technology.

"November 1980.""Serial HHH."At head of title: Committee print.Includes bibliographical references.M...

Revitalizing new product development from clinical trials through FDA review : hearing of the Committee on Labor and Human Resources, United States Senate, One Hundred Fourth Congress, second session, on S. 1477 ... February 21, 1996.

United States. Congress. Senate. Committee on Labor and Human Resources.

January 1996

Shipping list no.: 96-0240-P.Distributed to some depository libraries in microfiche.Includes bibliog...

FDA's reviews of new drugs : changes needed in process for reviewing and reporting on clinical studies /

Abstract

Extracted data

FDA's reviews of new drugs : changes needed in process for reviewing and reporting on clinical studies /

Abstract

Extracted data

Related items

Related items